Effect of Pioglitazone on Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus

Condition(s) targeted: Type 2 Diabetes Mellitus

Intervention: Pioglitazone (Actos) (Drug); Anti-diabetic agent other than pioglitazone or rosiglitazone (Drug)

Phase: Phase 1

Status: Recruiting

Sponsored by: Texas Tech University

Official(s) and/or principal investigator(s):
Chanwit Roongsritong, MD, Principal Investigator, Affiliation: TTUHSC

Overall contact:
Chanwit Roongsritong, MD, Phone: 806-743-3155, Email: chanwit.roongsritong@ttuhsc.edu

This study is being done to determine if pioglitazone (Actos) is helpful to patients with type 2 diabetes and could possibly prevent harmful consequences of cardiovascular disease in diabetic patients.

Official title: Effect of Pioglitazone on Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus

Study design: Other, Randomized, Open Label, Active Control, Parallel Assignment, Safety Study

Primary outcome:

Improvement in diastolic function parameters: early peak to late peak velocity (E/A) ratio

deceleration time (DT)

isovolumic relaxation time (IVRT)

E/A ratio percent change with Valsalva maneuver more than 40%

annular tissue Doppler velocity

Detailed description: Cross sectional and population-based studies indicate that at least one third of all patients with congestive heart failure (CHF) have a normal or near normal ejection fraction, which is thought to be secondary to diastolic dysfunction or failure. The mortality rates among the patients with diastolic failure ranges from 5-8% annually, as compared with 10-15% among patients with systolic heart failure. The morbidity associated with diastolic heart failure is similar to that of systolic heart failure. Several studies have shown that even simple Doppler evidence of diastolic dysfunction is an independent risk factor for the development of CHF and cardiac death and increased all cause mortality. Several studies indicate that left ventricular diastolic dysfunction (LVDD) represent the earliest preclinical manifestation of diabetic cardiomyopathy that can progress to symptomatic heart failure. Recent studies have demonstrated up to 60% of asymptomatic, normotensive patients with type 2 diabetes have LVDD when assessed by conventional echocardiography including the response to the Valsalva maneuver. A recent study using conventional Doppler, valsalva maneuver, color M-mode echocardiography and tissue doppler imaging assessed the diastolic dysfunction in asymptomatic normotensive patients with diabetes mellitus and found diastolic dysfunction in about 75% of these patients. Cardiovascular disease is the leading cause of death in patients with type 2 diabetes mellitus. Although diabetic patients have a large number of cardiovascular risk factors, like hyperlipidemia and hypertension, the diabetic cardiomyopathy occurs independent of these risk factors. Recently animal models have shown that LVDD may be prevented by chronic treatment with peroxisome-proliferator-activated receptors gamma (PPAR) agonists, like thiazolidinediones, in type 2 diabetic rats. Thiazolidinediones act through PPAR, but the exact mechanism by which they improve LVDD is not known. With this background knowledge, we wanted to study the effect of Pioglitazone, which is PPAR agonist and partial PPAR agonist, on the left ventricular diastolic dysfunction in type 2 diabetic human subjects, which has not been studied so far. If this therapy proves to have beneficial effect on the LVDD it will help in preventing the deleterious consequences of diastolic dysfunction in diabetic patients.

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. Patients with type 2 diabetes mellitus (DM)

2. Ages 18 to 65 years old

3. Patients with left ventricular diastolic dysfunction (LVDD) and ejection fraction (EF) > 50%

Exclusion Criteria:

1. Patients with uncontrolled hypertension

2. Patients with active myocardial ischemia with Canadian Cardiovascular Society (CCS) > II or known coronary artery disease (CAD)

3. Patients with atrial fibrillation

4. Patients with systolic heart failure

5. Patients with mitral regurgitation grade 2 or more

6. Patients with restrictive cardiomyopathy

7. Patients with constrictive pericarditis

8. Pregnant female patients

9. Recent stroke

10. Sepsis

11. Liver enzymes more than 2. 5 times the normal

12. Hemoglobin < 11g/dl or hematocrit < 30%

13. Terminal cancer

14. Patients on fibrates group of lipid lowering agents

15. Patients already on pioglitazone or rosiglitazone

16. Patients who are placed in the control group may not be currently taking a medication in the glitazones drug class.

17. Current or prior use of Pioglitazone or Rosiglitazone within the preceding 6 months.

Chanwit Roongsritong, MD, Phone: 806-743-3155, Email: chanwit.roongsritong@ttuhsc.edu

TTUHSC, Lubbock, Texas 79430, United States; Recruiting
Chanwit Rongsritong, MD, Phone: 806-743-3155, Ext: 246, Email: chanwit.roongsritong@ttuhsc.edu
Mika R Pierce, RN, BSN, Phone: 806-743-3155, Ext: 279, Email: mika.pierce@ttuhsc.edu
Chanwit Roongsritong, MD, Principal Investigator
Ashwani Kumar, MD, Sub-Investigator

Starting date: June 2007
Ending date: June 2008
Last updated: June 22, 2007